par Ignatiadis, M;Litière, Saskia;Rothé, Françoise
;Riethdorf, Sabine;Proudhon, Charlotte;Fehm, T;Aalders, Kim K.C.;Forstbauer, Helmut;Fasching, P A;Brain, E;Vuylsteke, P;Guardiola, E;Lorenz, R;Pantel, K;Tryfonidis, Konstantinos;Janni, Wolfgang;Piccart, M;Sotiriou, Christos
;Rack, B;Pierga, J-Y
Référence Annals of oncology, 29, 8, page (1777-1783)
Publication Publié, 2018-03-01


Référence Annals of oncology, 29, 8, page (1777-1783)
Publication Publié, 2018-03-01
Article révisé par les pairs
Titre: |
|
Auteur: | Ignatiadis, M; Litière, Saskia; Rothé, Françoise; Riethdorf, Sabine; Proudhon, Charlotte; Fehm, T; Aalders, Kim K.C.; Forstbauer, Helmut; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, Konstantinos; Janni, Wolfgang; Piccart, M; Sotiriou, Christos; Rack, B; Pierga, J-Y |
Informations sur la publication: | Annals of oncology, 29, 8, page (1777-1783) |
Statut de publication: | Publié, 2018-03-01 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adult |
Aged | |
Antineoplastic Agents, Immunological -- administration & dosage -- adverse effects | |
Breast -- pathology -- surgery | |
Breast Neoplasms -- blood -- mortality -- therapy | |
Cardiotoxicity -- epidemiology -- etiology | |
Chemotherapy, Adjuvant -- methods | |
Disease-Free Survival | |
Female | |
Humans | |
Mastectomy | |
Middle Aged | |
Neoplastic Cells, Circulating -- drug effects | |
Receptor, ErbB-2 -- antagonists & inhibitors -- metabolism | |
Trastuzumab -- administration & dosage -- adverse effects | |
Langue: | Anglais |
Identificateurs: | urn:issn:0923-7534 |
info:doi/10.1093/annonc/mdy211 | |
info:pii/S0923-7534(19)34129-8 | |
info:pmid/29893791 |